Literature DB >> 2794065

Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice.

J Satoh1, H Seino, T Abo, S Tanaka, S Shintani, S Ohta, K Tamura, T Sawai, T Nobunaga, T Oteki.   

Abstract

We previously reported that administration of a streptococcal preparation (OK-432) inhibited insulitis and development of autoimmune diabetes in nonobese diabetic (NOD) mice and BB rats as animals models of insulin-dependent diabetes mellitus. In this study, we screened various cytokines that could be induced by OK-432 in vivo, for their preventive effect against diabetes in NOD mice. Among recombinant mouse IFN gamma, human IL1 alpha, human IL2, mouse granulocyte-macrophage colony-stimulating factor and human TNF alpha, only human TNF alpha suppressed insulitis and significantly (P less than 0.001) inhibited development of diabetes. NOD mice were the lowest producers of the mRNA of TNF and serum TNF on stimulation with OK-432 or with IFN gamma plus LPS, compared with C57BL/6, C3H/He, and Balb/c mice. The results imply a role for low productivity of TNF in the pathogenesis of autoimmune diabetes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794065      PMCID: PMC329797          DOI: 10.1172/JCI114304

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Administration of silica particles or anti-Lyt2 antibody prevents beta-cell destruction in NOD mice given cyclophosphamide.

Authors:  B Charlton; A Bacelj; T E Mandel
Journal:  Diabetes       Date:  1988-07       Impact factor: 9.461

2.  The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction.

Authors:  M R Shalaby; T Espevik; G C Rice; A J Ammann; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

3.  Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats.

Authors:  J Satoh; S Shintani; K Oya; S Tanaka; T Nobunaga; T Toyota; Y Goto
Journal:  Diabetes       Date:  1988-09       Impact factor: 9.461

4.  IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans.

Authors:  I L Campbell; A Iscaro; L C Harrison
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

5.  Regulation of MHC protein expression in pancreatic beta-cells by interferon-gamma and tumor necrosis factor-alpha.

Authors:  I L Campbell; L Oxbrow; J West; L C Harrison
Journal:  Mol Endocrinol       Date:  1988-02

6.  Cloning and expression in Escherichia coli of the gene for mouse tumor necrosis factor.

Authors:  T Shirai; N Shimizu; S Shiojiri; S Horiguchi; H Ito
Journal:  DNA       Date:  1988-04

7.  Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies.

Authors:  D V Serreze; E H Leiter
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

8.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.

Authors:  C O Jacob; H O McDevitt
Journal:  Nature       Date:  1988-01-28       Impact factor: 49.962

9.  Breeding of a non-obese, diabetic strain of mice.

Authors:  S Makino; K Kunimoto; Y Muraoka; Y Mizushima; K Katagiri; Y Tochino
Journal:  Jikken Dobutsu       Date:  1980-01

10.  Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines.

Authors:  G E Ranges; A Zlotnik; T Espevik; C A Dinarello; A Cerami; M A Palladino
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  48 in total

Review 1.  Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 2.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

Review 3.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 4.  MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases.

Authors:  C O Jacob; G D Lewis; H O McDevitt
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant.

Authors:  D Ulaeto; P E Lacy; D M Kipnis; O Kanagawa; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

6.  RFLP analysis of the MHC class III region defines unique haplotypes for the non-obese diabetic, cataract Shionogi and the non-obese non-diabetic mouse strains.

Authors:  T Lund; S Shaikh; E Kendall; R D Campbell; M Hattori; S Makino; A Cooke
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

7.  The role of cytotoxic macrophages in non-obese diabetic mice: cytotoxicity against murine mastocytoma and beta-cell lines.

Authors:  A Kasuga; T Maruyama; I Takei; A Shimada; T Kasatani; K Watanabe; T Saruta; T Nakaki; S Habu; J Miyazaki
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

8.  Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model.

Authors:  Cheryll Williams-Skipp; Thiagarajan Raman; Robert J Valuck; Herschel Watkins; Brent E Palmer; Robert I Scheinman
Journal:  Arthritis Rheum       Date:  2009-02

9.  Suppression of diabetes mellitus in the non-obese diabetic (NOD) mouse by an autoreactive (anti-I-Ag7) islet-derived CD4+ T-cell line.

Authors:  N Chosich; L C Harrison
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

10.  Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer.

Authors:  M J Clare-Salzler; J Brooks; A Chai; K Van Herle; C Anderson
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.